224
Views
41
CrossRef citations to date
0
Altmetric
Original Articles

Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030

, , , , , , , , , , , , , , , & show all
Pages 143-152 | Published online: 06 Jan 2015

REFERENCES

  • Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis. 1992;14:608–615.
  • Jackson JB, Erice A, Englund JA, Edson JR, Balfour HH. Prevalence of cytomegalovirus antibody in hemophili-acs and homosexuals infected with human immunodefi-ciency virus type 1. Transfusion. 1988;28:187–189.
  • Lang DJ, Kovacs AA, Zaia JA, et al. Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infec-tions in relation to human immunodeficiency virus type 1 infection in selected recipient populations. J Acquir Immune Defic Syndr 1989;2:540–549.
  • Clarke LM, Duerr A, Feldman J, et al. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban minority community. J Infect Dis. 1996;173(1):77–82.
  • Spector SA, Wong R, Hsia K, et al. Plasma cytomegalovi-rus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest. 1998;101:497–502.
  • Spector SA, Hsia K, Crager M, et al. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J ViroL 1999;73:7027–7030.
  • Casado JL, Arrizabalaga J, Montes M, et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS. 1999;13:1497–1502.
  • Salmon-Ceron D, Mazeron MC, Chaput S, et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS. 2000;14(8):1041–1049.
  • Erice A, Tierney C, Hirsch M, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). Clin Infect Dis. 2003;37:567–578.
  • Deayton JR, Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viremia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet. 2004;363:2116–2121.
  • Wohl DA, Zeng D, Stewart P, et al. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. J Acquir Immune Defic Syndr 2005;38(5):538–544.
  • Regulatory Compliance Center, Division of AIDS. Table for grading the severity of adult and pediatric adverse events. Available at: http://rcc.tech-res.com/tox_tables.html. Accessed February 8,2009
  • Fundus Photography Reading Center, University of Wisconsin. Nine Standard Field Protocol for Fundus Pho-tography. Available at: http://eyephoto.ophth.wisc.edu/Photography/Protocols/AIDS/AIDSPhotoProtocolhtml.. Accessed February 8,2009
  • Gray RJ. A class of k-sample test for comparing the cumulative incidence of a competing risk. Ann Statistics. 1988;16:1141–1154.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.